NEWS
Discover recent news, press, publications & congress and industry news below.
![news-banner](https://anthostherapeutics.com/wp-content/uploads/2023/10/news-banner.png)
For access to a press kit, please contact a member of the media team at info@anthostherapeutics.com.
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab
Jun 6, 2024 | NEW RELEASES
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke NEWS PROVIDED BY Anthos Therapeutics June 6, 2024 08:15 ET 75% of...
First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor
May 6, 2024 | NEW RELEASES
First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant NEWS PROVIDED BY Anthos Therapeutics May 6, 2024 10:32 ET Treatment...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
Apr 22, 2024 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics April 22, 2024 11:00 ET CAMBRIDGE, Mass., – April 22, 2024 – Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS),...
Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
Nov 12, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics → November 12, 2023 08:15 ET Secondary Endpoints Also Showed a Highly Significant 74% Reduction in Major Bleeding and a 93% Reduction in Gastrointestinal (GI) Bleeding with Abelacimab These Results Triggered the Data Monitoring...
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Sep 26, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 26, 2023 07:00 ET Study Participants May Transition from the Rivaroxaban Arm to Abelacimab in an Extension Study CAMBRIDGE, Mass., September 26, 2023 (BUSINESS WIRE) – Anthos Therapeutics, Inc., a clinical stage...
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
Sep 18, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 18, 2023 06:00 ET Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-to-Head Study Comparing a Factor XI Inhibitor to a DOAC Abelacimab...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
Jun 26, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 26, 2023, 02:00 ET Patient-Centric Survey Conducted in Collaboration with StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology, Capturing...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
Jun 8, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 08, 2023 11:10 ET Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 9, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 09, 2023 09:45 ET Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient Issues to the...
Anthos Therapeutics to Present Four Posters at ISPOR 2023
May 5, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 05, 2023 08:00 ET Additional presentation spotlights GARDENIA registry design in patients with atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer Associated...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
Jan 3, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jan 3, 2023, 08:00 ET FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3 study with...
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Sep 8, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Sept 08, 2022, 08:00 ET This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
Aug 25, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics -> Aug 25, 2022, 08:00 ET Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...
Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
Jul 13, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jul 11, 2022, 02:00 ET Additional Pharmacodynamic Data on Abelacimab Released at the 2022 Congress of the International Society on Thrombosis and Haemostasis (ISTH) CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos...
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Jul 11, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jul 11, 2022, 02:00 ET Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high af nity and selectivity Earlier this year abelacimab became the rst-ever Factor XI inhibitor to...
Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience
May 26, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 26, 2022, 08:00 ET CAMBRIDGE, Mass., May 26, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the...
Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
May 13, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jun 13, 2022, 08:00 ET CAMBRIDGE, Mass., June 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that it...
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
May 5, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 05, 2022, 14:28 ET Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high af nity and selectivity Robust phase 3 clinical program includes two complementary trials...
Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer
Jan 5, 2022 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jan 05, 2022, 08:00 ET CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the...
Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment
Dec 7, 2021 | NEW RELEASES
Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment NEWS PROVIDED BY Anthos Therapeutics Dec 07, 2021, 08:00 ET CAMBRIDGE, Mass., Dec. 7, 2021 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company...
Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
Jul 19, 2021 | NEW RELEASES
Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine Abelacimab achieved a ~80% reduction in venous...